VaxGen has been developing its anthrax vaccine candidate, rPA102, to address the urgent need for a modern recombinant vaccine, based on a single defined protein, that has a strong safety profile and which provides protective immunity when administered in a three-dose schedule. The present vaccine requires the administration of six doses.
The UCLA Center for Vaccine Research, located at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) in Torrance, California, is currently participating in a VaxGen rPA102 vaccine research study. The current study is designed to find the anthrax vaccine formulation that will provide the best safety profile (or fewest side effects), while providing the highest level of protection (or best immune response) against anthrax. In the current study, 45 healthy adults were enrolled at the Vaccine Center. The Center is hoping to participate in future studies to determine the best vaccine schedule.
For information about future anthrax studies or the testing of this vaccine, contact the Director of the UCLA Center for Vaccine Research, Joel I.Ward, MD, at 1-800-637-8860.
Dr. Chad K. Oh co-authors "How to Live with a Nut Allergy"
Dr. Chad K.Oh, a principal investigator at LA BioMed, has co-authored a new book titled "How to Live with a Nut Allergy" (McGraw-Hill, $14.95). Every year, 100 Americans die after eating nuts or peanuts. For the 1.5 million Americans living with nut allergies, even slight exposure, such as eating with a fork t
Contact: David Feuerherd
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)